Aradigm (ARDM) Reaches New 12-Month High at $5.74
Shares of Aradigm Corporation (NASDAQ:ARDM) reached a new 52-week high during trading on Thursday . The stock traded as high as $5.74 and last traded at $5.53, with a volume of 271200 shares changing hands. The stock had previously closed at $5.00.
Several analysts have recently commented on ARDM shares. Zacks Investment Research upgraded shares of Aradigm from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a research report on Wednesday, August 30th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and issued a $10.00 price target (up from $7.50) on shares of Aradigm in a research report on Monday, September 25th.
The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of -1.59.
Aradigm (NASDAQ:ARDM) last announced its earnings results on Thursday, November 2nd. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.05. Aradigm had a negative net margin of 118.37% and a negative return on equity of 665.03%. The firm had revenue of $2.73 million for the quarter. analysts forecast that Aradigm Corporation will post -0.74 earnings per share for the current year.
A hedge fund recently bought a new stake in Aradigm stock. Jane Street Group LLC bought a new position in shares of Aradigm Corporation (NASDAQ:ARDM) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 29,025 shares of the company’s stock, valued at approximately $122,000. Jane Street Group LLC owned about 0.19% of Aradigm as of its most recent filing with the Securities and Exchange Commission (SEC). 32.08% of the stock is currently owned by institutional investors.
Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.
Receive News & Ratings for Aradigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm and related companies with MarketBeat.com's FREE daily email newsletter.